Osteogenesis imperfecta type 6 is a rare genetic condition that causes fragile bones and frequent fractures. It is usually recognized in infancy or early childhood and tends to be lifelong. People with osteogenesis imperfecta type 6 often have bone pain, short stature, and delayed motor milestones, and doctors may see low bone density on scans. Treatment focuses on fracture prevention, splints or surgery for bone support, physical therapy, and medicines that strengthen bone such as bisphosphonates. The outlook varies, but many people live long lives with careful orthopedic and rehabilitation care.
Overview
Osteogenesis imperfecta type 6Symptoms
Osteogenesis imperfecta type 6 features fragile bones, frequent fractures with minor falls, and poor bone density. Early signs of osteogenesis imperfecta type 6 include bowed legs, spine curvature, and short stature, usually noticed in infancy or early childhood. Teeth usually normal.
Outlook and prognosis
Most children with osteogenesis imperfecta type 6 grow into adulthood, but bone fragility and frequent fractures can continue. With tailored care—fracture prevention, physical therapy, and bone-strengthening medicines—many gain mobility, reduce pain, and protect function. Outlook varies; regular follow-up helps adjust support over time.
Causes and risk factors
Osteogenesis imperfecta type 6 results from inherited changes in SERPINF1, usually autosomal recessive. Risk rises when both parents are carriers, with family history, or consanguinity. Nutrition, vitamin D status, and activity level may modify bone fragility, not cause it.
Genetic influences
Genetics play a central role in osteogenesis imperfecta type 6; it’s caused by inherited or new changes in a gene affecting bone mineralization. These variants disrupt normal bone strength. Genetic testing can confirm the diagnosis, guide care, and inform family planning.
Diagnosis
Doctors suspect Osteogenesis imperfecta type 6 based on frequent fractures, low bone density, and characteristic X‑ray findings. Genetic tests (often SERPINF1) confirm the diagnosis; occasionally, bone biopsy helps. Ask about genetic diagnosis of Osteogenesis imperfecta type 6 when evaluation begins.
Treatment and drugs
Treatment for osteogenesis imperfecta type 6 focuses on strengthening bone, easing pain, and preventing fractures. Care often includes bisphosphonates, calcium and vitamin D, tailored physical therapy, safe activity, bracing, and surgery like rodding to support fragile long bones. Regular dental, hearing, and spine checks guide adjustments over time.
Symptoms
Living with Osteogenesis imperfecta type 6 often means bones that break more easily than expected, sometimes after small bumps or falls. Parents may first notice early features of Osteogenesis imperfecta type 6 such as fractures with minor falls and delays in sitting or walking. These changes can affect mobility, growth, and confidence during play and school. Features vary from person to person and can change over time.
Bones may break after minor falls or everyday bumps. In Osteogenesis imperfecta type 6, fractures often begin in late infancy or early childhood. Recurrent casts or splints can interrupt play and school.
Repeated fractures can lead to curved legs or arms and changes in the rib cage or pelvis. In Osteogenesis imperfecta type 6, these changes may make standing, walking, or fitting into standard clothing and car seats harder.
Scoliosis or a rounded back can develop as the spine’s bones compress over time. This can cause back pain and reduce height. If the chest shape changes, breathing may feel harder during colds.
Many children grow to be shorter than peers due to frequent vertebral compression and long-bone changes. Height differences are often more noticeable by school age.
How people usually first notice Osteogenesis imperfecta type 6?
Many families first notice something is off when a baby or toddler has bone fractures after minimal bumps or falls, or persistent bone pain without a clear injury. Doctors may see poor bone mineralization on X‑rays, delayed walking, or bowed legs, and sometimes a vertebral compression fracture shows up after the first months of life, which raises concern for osteogenesis imperfecta type 6. Because type 6 often lacks the classic blue sclerae seen in other types, the first signs of osteogenesis imperfecta type 6 are usually repeat fractures and low bone density that become apparent in late infancy or early childhood rather than right at birth.
Types of Osteogenesis imperfecta type 6
Osteogenesis imperfecta type 6 is a genetic bone fragility disorder with a recognizable pattern but some variability in how it shows up day to day. Many living with this condition have frequent fractures, bone pain, and slower healing, which can affect walking, school, and play. Researchers describe these categories to better understand patterns of the condition. When people search for types of Osteogenesis imperfecta type 6, they’re often asking how mild versus more severe courses differ and what that means for symptoms over time.
Milder course
Fractures happen but less often than in severe forms. Growth may be closer to average, with shorter height becoming more noticeable later in childhood. Spine curves and chest shape changes are usually mild.
Moderate course
Fractures are more frequent and can occur with minor falls. Short stature and bowing of long bones are common, and walking may need bracing at times. Bone pain and fatigue can flare after activity.
Severe course
Fractures occur early and often, including vertebral compression in the spine. Marked short stature and significant limb deformities can limit mobility and daily tasks. Breathing problems may appear if the chest wall is affected.
Early-childhood onset
Symptoms begin after a period of typical infancy, often when standing or walking starts. Fractures cluster in the toddler years and early school age. Healing may be slow, with visible thickening at old fracture sites.
Calcium-handling phenotype
Bone scans and biopsies show poor mineralization with distinctive band-like patterns. People may have low bone density despite normal blood calcium and vitamin D. This pattern helps doctors confirm variants of Osteogenesis imperfecta type 6.
What genetics can tell you about symptoms
In osteogenesis imperfecta type 6, mutations in the SERPINF1 gene reduce a protein that helps bones mineralize, leading to fragile bones. People may have frequent low‑impact fractures, delayed walking, bone pain, and vertebral compression, with normal teeth and blue sclera typically absent.
Causes and risk factors
Osteogenesis imperfecta type 6 is caused by changes in a gene called SERPINF1.
It is usually inherited in an autosomal recessive pattern, meaning both copies of the gene need to be changed.
This happens when both parents are carriers, and the chance is higher if the parents are related.
Doctors distinguish between risk factors you can change and those you can’t.
Risk factors for Osteogenesis imperfecta type 6 center on family history or carrier status, while nutrition, vitamin D and calcium, safe activity, and growth spurts can shape severity but do not cause the condition.
Environmental and biological risk factors
Osteogenesis imperfecta type 6 is present from very early development, so most influences on whether it occurs are body-based rather than things you do during pregnancy or in the environment. Doctors often group risks into internal (biological) and external (environmental). For this rare subtype, environmental and biological risk factors for osteogenesis imperfecta type 6 are not clearly defined; there are no well-established environmental triggers, and common prenatal health factors have not been shown to raise the chance of having a child with it. Research is ongoing, and findings are limited because the condition is uncommon.
Advanced maternal or paternal age has not been shown to increase the likelihood of osteogenesis imperfecta type 6. Both younger and older parents have had children with this subtype.
Common maternal conditions such as diabetes, thyroid disease, or high blood pressure have not been linked to higher risk. Current evidence does not show these biological factors change the chance of the condition.
Infections during pregnancy have not been shown to trigger the condition. They may affect overall pregnancy health, but they do not appear to change the likelihood of this condition.
Typical environmental exposures such as air pollution, hormone‑disrupting chemicals, or heavy metals have no established link to osteogenesis imperfecta type 6 occurring. High‑dose ionizing radiation is harmful in general, but specific ties to this subtype are not proven.
Genetic risk factors
The genetic causes of Osteogenesis imperfecta type 6 center on changes in a single gene called SERPINF1, which disrupt normal bone mineralization. This type follows an autosomal recessive pattern, meaning a child is affected when both copies of the gene carry harmful changes, usually inherited from carrier parents. In some cases, genetic testing can give a clearer picture of your personal risk. Understanding the genetic causes of Osteogenesis imperfecta type 6 can help families plan, from carrier testing to options for future pregnancies.
SERPINF1 gene changes: Most cases are due to harmful changes in the SERPINF1 gene, which lower or eliminate a protein that helps bones mineralize. When the protein is missing, bone tissue forms but doesn't harden properly, increasing fracture risk from early childhood.
Autosomal recessive: A child is affected when they inherit one non-working SERPINF1 copy from each parent. Parents are typically healthy carriers with one working copy and often no symptoms. This pattern affects all genders equally.
Carrier couple risk: When both parents are carriers, each pregnancy has a 25% chance of Osteogenesis imperfecta type 6. There is also a 50% chance the child will be an unaffected carrier and a 25% chance of inheriting two working copies. These odds repeat with every pregnancy.
Sibling chances: Full siblings of someone with Osteogenesis imperfecta type 6 have a 2 in 3 chance of being carriers if they are not affected. Carrier siblings typically have no symptoms but can pass the gene change to their children.
Parental relatedness: When parents are related by blood, they are more likely to carry the same SERPINF1 change by chance. This raises the likelihood of having a child with the condition compared with unrelated couples.
Gene not working: Most known SERPINF1 changes stop the gene from working, rather than subtly changing its function. Testing can often identify the exact change, which helps clarify carrier status in relatives.
Genetic testing: A DNA test that looks at SERPINF1 can confirm the diagnosis and whether changes are present in one or both copies. Results guide carrier testing for family members and options for prenatal or preimplantation testing.
Not collagen genes: Unlike several other forms of OI, type 6 is not caused by changes in the main collagen genes. This difference can explain why collagen studies are often normal while bones are still fragile.
Lifestyle risk factors
Osteogenesis imperfecta type 6 is a genetic bone fragility disorder; lifestyle habits do not cause it, but they can meaningfully influence pain, mobility, and fracture risk. Understanding how lifestyle affects Osteogenesis imperfecta type 6 can help tailor daily routines to protect bones and support function. The elements below focus on day-to-day choices that may reduce fractures and improve quality of life.
Jumping, contact sports, and abrupt twisting place high stress on fragile bones and raise fracture risk. Choosing low-impact options like swimming or cycling can build fitness with less bone load.
Targeted strength, balance, and flexibility work can improve gait stability and reduce falls. Physiotherapist-guided or aquatic programs help train safely while avoiding overload.
Adequate intake from foods and safe sun exposure supports mineralization in inherently weak bone. Inadequacy can worsen low bone density and increase fracture frequency.
Sufficient protein and overall calories support collagen matrix repair and post-fracture healing. Poor intake can slow recovery and reduce muscle strength that protects bones.
Risk prevention
Osteogenesis imperfecta type 6 is a genetic bone condition, so you can’t prevent the condition itself, but you can lower the risk of fractures and long-term complications. For many, this means building bone strength, avoiding falls, and staying on top of medical care from childhood onward. Even if you can’t remove all risks, prevention can reduce their impact. If future family planning is a consideration, genetic counseling can help clarify options to reduce the chance of passing on OI type 6.
A physical therapist can teach joint-safe ways to sit, stand, lift, and turn. Learning how to fall more safely can reduce fractures in osteogenesis imperfecta type 6.
Braces, splints, shoe inserts, or mobility aids can steady joints and improve balance. Better stability lowers the chance of falls and bone stress in OI type 6.
Remove tripping hazards, add non-slip mats, and use good lighting on stairs and hallways. Simple changes at home can cut everyday fall risk.
Aim for enough calcium and vitamin D through food and supplements if advised. Good levels support bone mineralization in OI type 6.
Transmission
Osteogenesis imperfecta type 6 is not infectious; it can’t be caught or spread through everyday contact. Most often, it is inherited in an autosomal recessive pattern: both parents carry one changed copy of a gene important for bone strength without symptoms, and with each pregnancy there is a 25% (1 in 4) chance the child will have osteogenesis imperfecta type 6, a 50% (1 in 2) chance the child will be a carrier, and a 25% chance the child will be unaffected. It can appear in a family with no prior history because parents may be silent carriers, and very rarely it can result from a new genetic change. If you have questions about the genetic transmission of osteogenesis imperfecta type 6 or how osteogenesis imperfecta type 6 is inherited, a genetics professional can review carrier testing and family risk.
When to test your genes
Osteogenesis imperfecta type 6 is a genetic condition; genetic testing is helpful when unexplained fractures, low bone density, or family history suggest OI, to confirm the diagnosis and guide care. Test before or early in treatment to tailor medications, physical therapy, and surgical planning. Consider testing for relatives planning pregnancies.
Diagnosis
For many families, the road to answers starts when a child has repeated fractures from everyday bumps or short falls. Doctors usually begin with a careful exam and imaging, then confirm findings with targeted tests. Because this is a genetic condition, results from DNA testing can be especially helpful. A genetic diagnosis of Osteogenesis imperfecta type 6 is often made by combining clinical clues with radiology and, if needed, specialized testing.
Recurrent fractures after minimal trauma raise suspicion, often without the blue-tinged eyes or tooth changes seen in other types. Growth may be slower, and there can be spine curves or limb bowing. Pain between injuries can vary.
A full set of X-rays looks for low bone density, healed fractures, and vertebral compression. These imaging findings help separate Osteogenesis imperfecta type 6 from injuries due to accidents or other bone disorders. From here, the focus shifts to confirming or ruling out possible causes.
A DXA scan measures bone mineral density and often shows low values for age. This helps document severity and provides a baseline for future comparison. It does not by itself confirm the type.
Sequencing tests look for changes in the SERPINF1 gene, the known cause of Osteogenesis imperfecta type 6. If this single-gene test is negative, a broader bone fragility panel may be considered. Genetic testing may be offered to clarify risk or guide treatment.
Stages of Osteogenesis imperfecta type 6
Osteogenesis imperfecta type 6 does not have defined progression stages. It tends to be a lifelong pattern of bone fragility that varies from person to person, with fractures happening in episodes—often more in childhood—and not in predictable stages. For many, the early symptoms of Osteogenesis imperfecta type 6 show up as frequent fractures with minor bumps or falls, sometimes with slow healing. Different tests may be suggested to help confirm the diagnosis and track bone health, such as X-rays, bone density scans, and genetic testing.
Outlook and prognosis
Many people ask, “What does this mean for my future?”, and with osteogenesis imperfecta type 6 the picture depends on how severe the bone fragility is in a given person. The outlook is not the same for everyone, but many children have frequent fractures in early childhood and slower bone healing, then see fracture rates lessen as growth stabilizes. Height is often below average, and some develop spine curves or chest shape differences that can affect stamina, though most people with osteogenesis imperfecta type 6 have a normal lifespan.
Looking at the long-term picture can be helpful. With consistent care—usually a mix of physical therapy, fall-prevention strategies, vitamin D and calcium optimization, and bone-strengthening medicines—many people maintain mobility using braces, walkers, or wheelchairs as needed. Early care can make a real difference, because treating early symptoms of osteogenesis imperfecta type 6 such as recurrent fractures or delayed walking can improve bone density, muscle strength, and confidence with movement. Severe cases may face higher surgical needs for rods in long bones and monitoring for spinal compression or chest restriction, which can raise complication risks, including pneumonia, but modern care has reduced serious complications for many.
Prognosis refers to how a condition tends to change or stabilize over time. Children often need more interventions, while adults may shift to maintaining bone health, preventing falls, and managing chronic pain. Not everyone with the same gene change will have the same outlook, and some families see milder patterns than others. Talk with your doctor about what your personal outlook might look like, including fracture risk, plans for surgery or therapy, and how to stay active and safe at home and school or work.
Long-term effects
Osteogenesis imperfecta type 6 is a lifelong genetic bone fragility condition that often shows the most impact in childhood and adolescence. Long-term effects vary widely, with some people having frequent fractures and noticeable bone changes while others have milder, steadier issues. Thinking about the long-term effects helps families plan for school, work, and independence as needs evolve. Clinicians often follow people over time to watch growth, mobility, and spine shape, which informs the long-term outlook for osteogenesis imperfecta type 6.
In osteogenesis imperfecta type 6, fractures often happen repeatedly in childhood and early teens. The pace usually slows after puberty.
Healed fractures and softer bone can lead to bowing of the long bones. This may change limb alignment and overall body shape over time.
Slower growth and compressed vertebrae can result in a shorter adult height. Final height varies widely among people with osteogenesis imperfecta type 6.
Vertebral compression and scoliosis or kyphosis can develop. These spine changes may progress during growth spurts and then stabilize in adulthood.
How is it to live with Osteogenesis imperfecta type 6?
Living with osteogenesis imperfecta type 6 often means planning your day around bone safety and energy. Many deal with frequent fractures in childhood, slower healing, and chronic or activity‑related pain, so school, work, and sports may require adaptive equipment, mobility aids, and extra time. Families and friends usually become part of the care routine—helping with transportation, home modifications, and encouragement—while learning how to assist safely without limiting independence. With knowledgeable care teams, tailored physical therapy, and supportive communities, many build stable routines that protect bones while making room for joy, movement, and personal goals.
Treatment and drugs
Treatment for Osteogenesis imperfecta type 6 focuses on strengthening bones, reducing pain, and preventing fractures through a mix of medicines, nutrition, movement, and careful surgical support when needed. Bisphosphonates are commonly used to increase bone density, and many care teams also ensure adequate calcium and vitamin D, tailor safe, low-impact physiotherapy, and use braces or casts to protect healing bones. In children and adults with repeated fractures or severe bowing, surgeons may place metal rods to stabilize long bones and improve mobility; a wheelchair, walker, or custom orthotics may help during recovery or for longer-term support. Finding the right therapy can take some time, with regular check-ins to adjust dosing, monitor side effects, and update exercise or bracing plans as needs change. Ask your doctor about the best starting point for you, including whether clinical trials or newer bone-building medicines could be appropriate.
Non-drug treatment
Daily care for osteogenesis imperfecta type 6 focuses on protecting bones, building strength, and staying mobile. Alongside medicines, non-drug therapies can reduce fractures, improve function, and support independence. Providers also watch for early symptoms of osteogenesis imperfecta type 6, like delayed walking or frequent fractures, to tailor therapy intensity. Plans change with age and severity, and often combine home strategies with specialist-led care.
Gentle, regular movement helps maintain strength, balance, and range of motion. Programs are customized to avoid high-impact stress that could trigger fractures.
Low-impact activities like walking in water or cycling on a stationary bike can build endurance. Short, frequent sessions lower strain while supporting bone and muscle health.
Water supports the body and reduces pressure on fragile bones. Guided pool exercises can improve mobility and confidence for people with osteogenesis imperfecta type 6.
Custom braces or shoe inserts can improve alignment and reduce fracture risk during daily activities. They may also ease pain and fatigue by supporting weak joints.
Your genes may have an impact on how drugs work for you
Even with the same diagnosis of osteogenesis imperfecta type 6, people can process medications differently because variants in drug‑handling genes affect absorption, breakdown, and response. This can influence dosing or choice of pain control, bisphosphonates, or anesthesia strategies.
Pharmacological treatments
Medicines for osteogenesis imperfecta type 6 aim to reduce fractures, ease pain, and improve bone strength, especially during growth spurts. Not everyone responds to the same medication in the same way. Type 6 may respond less strongly to some standard bone medicines than other forms, so treatment is usually tailored in a specialist center. While medicines don’t change early symptoms of osteogenesis imperfecta type 6, they can help protect bones over time and support rehab and physical therapy.
Pamidronate and zoledronic acid are often used to slow bone breakdown and improve bone density. They are given through a vein every few months under specialist supervision. Blood tests and dental checks help lower the risk of rare side effects.
Alendronate or risedronate may be used when IV access is difficult or between infusions. These pills are taken on an empty stomach with water and staying upright afterward to protect the esophagus. Doctors monitor bone density and symptoms to judge benefit.
This injection can be considered off-label in type 6 when bisphosphonate response is limited. It may improve bone density but needs careful monitoring for low calcium and rebound effects between doses. Supplements and regular blood tests are typically part of the plan.
Daily supplements help ensure building blocks for bone are available, alongside a balanced diet. Levels are checked to avoid too little or too much. Sunlight exposure and dietary intake are reviewed at visits.
Genetic influences
In most people, osteogenesis imperfecta type 6 results from inherited changes in a single gene that helps bones mineralize properly. These changes usually involve a gene called SERPINF1, and both copies need to be altered—one from each parent—for the condition to appear (this is an autosomal recessive pattern). A “carrier” means you hold the gene change but may not show symptoms. When both parents are carriers, each pregnancy has a 25% chance of a child having osteogenesis imperfecta type 6, a 50% chance of a child being a carrier, and a 25% chance of neither. This form differs from many other types of osteogenesis imperfecta that involve collagen genes; here, the pathway mainly affects how bone hardens rather than how collagen is built. Genetic testing for osteogenesis imperfecta type 6 can confirm a SERPINF1 change, guide family planning, and help relatives understand their own risks.
Is Osteogenesis imperfecta type 6 genetic?
Genetics play a central role in osteogenesis imperfecta type 6; it’s caused by inherited or new changes in a gene affecting bone mineralization. These variants disrupt normal bone strength. Genetic testing can confirm the diagnosis, guide care, and inform family planning.
Pharmacogenetics—how genetics influence drug effects
In osteogenesis imperfecta type 6, the specific gene change alters how bones mineralize, which can affect how well bone‑strengthening medicines work. Drugs that slow bone breakdown (bisphosphonates) may offer less benefit in osteogenesis imperfecta type 6 than in some other types, so doctors may adjust dosing or consider alternatives like denosumab, with careful monitoring of calcium and vitamin D during and after treatment. Response also varies with age, mobility, nutrition, and other health conditions, so your plan may change over time. Genetic testing can sometimes identify how your body handles certain pain medicines used after fractures or surgery, which may help choose safer, more effective options. Taken together, this helps tailor medications for osteogenesis imperfecta type 6 to fit your situation.
Interactions with other conditions
Other health issues can change how fragile bones behave day to day—especially anything that affects bone strength, muscles, or breathing. In Osteogenesis imperfecta type 6, vitamin D deficiency, low calcium intake, celiac disease or other gut absorption problems, and long-term steroid use can lower bone density in Osteogenesis imperfecta type 6 and raise fracture risk. Respiratory conditions such as asthma or recurrent chest infections can strain a curved spine or soft chest wall, making breathing and activity harder. A condition may “exacerbate” (make worse) symptoms of another. Thyroid overactivity, chronic kidney or liver disease, and certain seizure medicines can also weaken bones, so medication lists matter. Let your care team know about all diagnoses and treatments so they can coordinate care, optimize nutrition and medications, and tailor safe movement and fall-prevention plans.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Families and communities once noticed patterns of unusually fragile bones that broke with minor bumps, then slowly realized some children had this tendency while their siblings did not. In everyday life, this could look like a toddler who fractures a leg after a short fall from a couch, heals, and then months later breaks an arm during gentle play. These stories traveled across generations, long before anyone knew the specific type or the gene involved.
First described in the medical literature as a broader condition of “brittle bone disease,” osteogenesis imperfecta included several subtypes grouped by how severe the bone fragility seemed. Osteogenesis imperfecta type 6 was not recognized at first. It emerged later, as clinicians noticed a subset of children whose bones showed a distinctive pattern on biopsy and who did not respond to standard treatments in the same way as others. From these first observations, specialists began to separate type 6 from other forms based on the look of the bone under the microscope and the clinical course.
In recent decades, awareness has grown that osteogenesis imperfecta is not a single condition but a family of related disorders, each with its own cause and typical features. For osteogenesis imperfecta type 6, careful clinical records and shared case series helped outline the early symptoms of type 6 and the way fractures tended to recur during childhood. This stepwise work led to more accurate diagnosis, better counseling for families, and more realistic expectations about treatment responses.
Advances in genetics eventually clarified the picture. Researchers identified changes in a specific gene that affects how bone mineral is laid down, helping explain why bone in osteogenesis imperfecta type 6 looks different and can be more prone to breaking. This genetic insight also showed why some medicines helped less than expected, guiding teams toward tailored care plans and closer monitoring.
Over time, the way the condition has been understood has changed as more children and adults with osteogenesis imperfecta type 6 were described from different regions and backgrounds. Clinicians learned that severity can vary: some people walk independently with occasional fractures, while others need mobility aids and more frequent care. Historical differences highlight why naming the type correctly matters, because it shapes decisions about imaging, dental and spine checks, and bone-strengthening strategies.
Today’s approach builds on decades of observation, careful bone studies, and genetic research. Knowing the condition’s history helps families understand why doctors may recommend specific tests, why responses to treatment can differ from other osteogenesis imperfecta types, and how care continues to improve as new findings are woven into practice.